Labubu fever, and a skincare brawl
An early edition toy based on the red-hot Labubu character has fetched a record $150,000 in a recent auction. What's driving the craze, and is it sustainable? And a high-profile tussle between two leading skincare brands has left one of them bruised, with its stock down 30%. How can investors steer clear of this kind of damage?
Biogene gets bruised in ‘Battle of the skincare belles’
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight Key Takeaways: Shares of Giant Biogene…
Beauty Products Maker Imeik Makes Second Try at Hong Kong IPO
With ultra-high gross margins, the Chinese maker of wrinkle fillers makes second attempt at secondary listing in Hong Kong Key Takeaways: Started in 2004, Imeik is the largest provider of…
Recent Articles
RELATED ARTICLES
-
Biogene gets bruised in ‘Battle of the skincare belles’
2367.HK 688363.SHG
-
INDUSTRY NEWS WRAP:First-edition Labubu sells for record $150,300
9992.HK
-
Yatsen CEO declares turnaround with quarterly non-GAAP profit
YSG.US
-
Miniso struggles to impress investors, even with a successful ‘toy story’
9896.HK MNSO.US
- Game time for another IPO hopeful in China’s booming toy market
-
QuantaSing excites investors with new toy tune
QSG.US
- 52Toys taps China’s designer toy boom in play for Hong Kong IPO
